Flavivirus vaccines
- PMID: 2854336
- DOI: 10.1016/0264-410x(88)90095-3
Flavivirus vaccines
Abstract
Diseases caused by flavivirus infection have been a scourge of mankind for over three centuries; with yellow fever, dengue fever and Russian spring-summer encephalitis causing epidemics resulting in thousands of fatalities. Due to the development of a safe and efficacious live-attenuated vaccine against yellow fever, this disease is no longer such a threat in countries where adequate vaccination is practised. A similarly safe and efficacious inactivated vaccine against central-European tick-borne encephalitis has also been developed and this has drastically reduced the incidence of this disease in many countries where it is endemic. In spite of these successes, the development of vaccines against other pathogenic flaviviruses, causing diseases such as dengue fever and Russian spring-summer encephalitis, have not been successful. This review attempts to summarize the development of flavivirus vaccines to date and identify areas for future improvements. Problems associated with designing flavivirus vaccines are discussed and the advantages and disadvantages of future strategies for vaccine development are considered.
Similar articles
-
Flaviviruses and flavivirus vaccines.Vaccine. 2012 Jun 19;30(29):4301-6. doi: 10.1016/j.vaccine.2011.09.114. Vaccine. 2012. PMID: 22682286 Review.
-
Current status of flavivirus vaccines.Ann N Y Acad Sci. 2001 Dec;951:262-71. doi: 10.1111/j.1749-6632.2001.tb02702.x. Ann N Y Acad Sci. 2001. PMID: 11797783 Review.
-
Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine.J Med Virol. 1985 Sep;17(1):35-45. doi: 10.1002/jmv.1890170106. J Med Virol. 1985. PMID: 2995571
-
Formalin-inactivated whole virus and recombinant subunit flavivirus vaccines.Adv Virus Res. 2003;61:395-418. doi: 10.1016/s0065-3527(03)61010-9. Adv Virus Res. 2003. PMID: 14714438 Review.
-
Towards a new generation of flavivirus vaccines.Vaccine. 1994 Aug;12(11):966-75. doi: 10.1016/0264-410x(94)90329-8. Vaccine. 1994. PMID: 7975848 Review.
Cited by
-
Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus.Arch Virol. 1996;141(3-4):743-9. doi: 10.1007/BF01718332. Arch Virol. 1996. PMID: 8645110
-
Genetic vaccination of mice with plasmids encoding the NS1 non-structural protein from tick-borne encephalitis virus and dengue 2 virus.Virus Genes. 2004 Jan;28(1):85-97. doi: 10.1023/B:VIRU.0000012266.04871.ce. Virus Genes. 2004. PMID: 14739654
-
Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein.J Virol. 2001 Apr;75(8):4002-7. doi: 10.1128/JVI.75.8.4002-4007.2001. J Virol. 2001. PMID: 11264392 Free PMC article.
-
Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus.PLoS Negl Trop Dis. 2007 Dec 12;1(3):e96. doi: 10.1371/journal.pntd.0000096. PLoS Negl Trop Dis. 2007. PMID: 18160988 Free PMC article.
-
Use of licensed vaccines for active immunization of the immunocompromised host.Clin Microbiol Rev. 1998 Jan;11(1):1-26. doi: 10.1128/CMR.11.1.1. Clin Microbiol Rev. 1998. PMID: 9457426 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources